The Worldwide Congestive Heart Failure (CHF) Treatment Devices Market is Projected to reach USD 16.5 Billion by 2028, at a CAGR of 5.4%
Special Offering :
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Congestive Heart Failure (CHF) Treatment Devices Market Growth, Trends and Report Highlights
According to a new report, published by KBV research, The Global Congestive Heart Failure (CHF) Treatment Devices Market size is expected to reach $16.5 billion by 2028, rising at a market growth of 5.4% CAGR during the forecast period.
The Implantable Cardioverter Defibrillators market is expected to witness a CAGR of 5.6% during (2022 - 2028). The increasing growth of this segment is attributed to its capacity to perform three main functions viz. Defibrillation, Cardioversion, and Cardiac pacing. Moreover, this is due to the fact that defibrillators and pacemakers are used as the first line of treatment for cardiac failure, Due to which, the demand for defibrillators. Hence, this factor is fueling the growth of this segment.
The North America market dominated the Global Congestive Heart Failure (CHF) Treatment Devices Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $5.9 Billion by 2028. The Europe market is estimated to witness a CAGR of 5.2% during (2022 - 2028). Additionally, The Asia Pacific market would experience a CAGR of 5.9% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/congestive-heart-failure-treatment-devices-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Boston Scientific Corporation, MicroPort Scientific Corporation, Abbott Laboratories, Medtronic PLC, Abiomed, Inc., Berlin Heart GmbH, Jarvik Heart, Inc., Lepu Medical Technology (Beijing) Co., Ltd., BIOTRONIK SE & Co. KG, and Osypka Medical GmbH.
Global Congestive Heart Failure (CHF) Treatment Devices Market Segmentation
By Product Type
- Pacemakers
- Implantable Cardioverter Defibrillators
- Cardiac Resynchronization Therapy
- Ventricular Assist Devices
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Boston Scientific Corporation
- MicroPort Scientific Corporation
- Abbott Laboratories
- Medtronic PLC
- Abiomed, Inc.
- Berlin Heart GmbH
- Jarvik Heart, Inc.
- Lepu Medical Technology (Beijing) Co., Ltd.
- BIOTRONIK SE & Co. KG
- Osypka Medical GmbH
Related Reports:
LAMEA Congestive Heart Failure (CHF) Treatment Devices Market Size, 2028
- May-2022
- 74 Pages
